Education
About Us
Working with TipRanks
Follow Us
Genscript Biotech (HK:1548)
:1548
1548 Stock Chart & Stats
HK$14.33
-HK$0.07(-0.74%)
At close: 4:00 PM EST
HK$14.33
-HK$0.07(-0.74%)
Day’s Range― - ―
52-Week RangeHK$9.45 - HK$19.40
Previous CloseN/A
Volume5.33M
Average Volume (3M)11.61M
Market Cap
HK$26.10B
Enterprise ValueHK$3.62B
Total Cash (Recent Filing)HK$938.36M
Total Debt (Recent Filing)HK$548.52M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 27, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding2,186,518,600
10 Day Avg. Volume8,707,016
30 Day Avg. Volume11,605,265
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.64
Price to Sales (P/S)4.64
P/FCF Ratio-38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong revenue growth across all segments indicates robust demand and successful execution of business strategies, supporting long-term expansion.
Strong Cash PositionA strong cash position enhances financial flexibility, enabling strategic investments in R&D and expansion, crucial for sustaining growth.
ESG AchievementsStrong ESG ratings reflect commitment to sustainability and governance, enhancing reputation and potentially attracting more investors.
Bears Say
Net Loss Due To Legend BiotechOngoing losses from Legend Biotech strain overall profitability, potentially impacting financial stability and investor confidence.
Temporary Gross Margin ImpactTemporary margin impacts could signal challenges in cost management, affecting short-term profitability and requiring strategic adjustments.
ProBio's Capacity ChallengesCapacity challenges in ProBio may hinder service delivery and margin recovery, affecting growth prospects if not addressed promptly.
Genscript Biotech News
1548 FAQ
What was Genscript Biotech’s price range in the past 12 months?
Genscript Biotech lowest stock price was HK$9.45 and its highest was HK$19.40 in the past 12 months.
What is Genscript Biotech’s market cap?
Genscript Biotech’s market cap is HK$26.10B.
When is Genscript Biotech’s upcoming earnings report date?
Genscript Biotech’s upcoming earnings report date is Mar 27, 2026 which is in 33 days.
How were Genscript Biotech’s earnings last quarter?
Genscript Biotech released its earnings results on Aug 17, 2025. The company reported -HK$0.172 earnings per share for the quarter, missing the consensus estimate of HK$0.625 by -HK$0.797.
Is Genscript Biotech overvalued?
According to Wall Street analysts Genscript Biotech’s price is currently Overvalued.
Does Genscript Biotech pay dividends?
Genscript Biotech pays a Notavailable dividend of HK$0.012 which represents an annual dividend yield of N/A. See more information on Genscript Biotech dividends here
What is Genscript Biotech’s EPS estimate?
Genscript Biotech’s EPS estimate is -0.23.
How many shares outstanding does Genscript Biotech have?
Genscript Biotech has 2,186,518,600 shares outstanding.
What happened to Genscript Biotech’s price movement after its last earnings report?
Genscript Biotech reported an EPS of -HK$0.172 in its last earnings report, missing expectations of HK$0.625. Following the earnings report the stock price went down -5.185%.
Which hedge fund is a major shareholder of Genscript Biotech?
Currently, no hedge funds are holding shares in HK:1548
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genscript Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
63.11%
Trailing 12-Months
Company Description
Genscript Biotech
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Technical Analysis
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---